Extravasation is the first step for nanomedicines in circulation to reach targeted solid tumors.
Traditional nanomedicines have been designed to extravasate into tumor interstitium …

Most solid tumors possess unique pathophysiological characteristics that are not observed
in normal tissues or organs, such as extensive angiogenesis and hence hypervasculature …

Nanocarriers can penetrate the tumour vasculature through its leaky endothelium and, in
this way, accumulate in several solid tumours. This is called the enhanced permeation and …

Currently, a majority of cancer treatment strategies are based on the removal of tumor mass
mainly by surgery. Chemical and physical treatments such as chemo-and radiotherapies …

Nanoparticles (NPs) have emerged as an effective means to deliver therapeutic drugs for
cancer treatment, as they can preferentially accumulate at tumor site through the enhanced …

Nanomedicine, the application of nanotechnology to treatment and prevention of diseases,
is an emerging form of drug therapy that utilizes nanomaterials as drug carriers for …

Nanomedicines including liposomes, micelles, and nanoparticles based on the enhanced
permeability and retention (EPR) effect have become the mainstream for tumor treatment …

Despite recent advances in the translation of therapeutic nanoparticles (TNPs) into the clinic,
the field continues to face challenges in predictably and selectively delivering nanomaterials …

Over the past few decades, enhanced permeability of tumor vasculature was actively
exploited for targeted delivery of anticancer nanomedicines resulting in numerous …

Blood vessels in tumors are different to normal blood vessels because they have abnormal
architectures and impaired functional regulation. We have studied these abnormalities, in …